AbbVie (NYSE:ABBV) Trading Up 3.7% – Should You Buy?

AbbVie Inc. (NYSE:ABBV) shares were up 3.7% on Thursday . The stock traded as high as $244.61 and last traded at $243.6470. Approximately 10,161,633 shares changed hands during mid-day trading, an increase of 49% from the average session volume of 6,812,379 shares. The stock had previously closed at $234.89.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord lifted its price target and said the Apogee acquisition strengthens AbbVie’s long-term growth outlook, signaling analyst confidence in the strategic fit of the deal. Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: AbbVie’s acquisition of Apogee is being highlighted as a potential blockbuster move that could add a de-risked, revenue-producing immunology asset to the pipeline. Is AbbVie a Buy After Its Purchase of Apogee?
• Positive Sentiment: AbbVie also received a boost from a new EU approval for Skyrizi in pediatric plaque psoriasis, which expands the drug’s addressable market and supports its immunology franchise. AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
• Neutral Sentiment: AbbVie’s Allergan Aesthetics unit earned Top 50 Status for 2026 from a partner, which is positive for brand momentum but likely not a major stock catalyst on its own. Formula Wellness Earns Top 50 Status for 2026 from Allergan Aesthetics
• Neutral Sentiment: AbbVie expanded its pipeline with a new early-stage bretisilocin safety study, but the trial is still in the early phase and should have limited near-term financial impact. AbbVie Expands Pipeline With New Bretisilocin Phase 1 Safety Study
• Negative Sentiment: Some investors remain cautious about the size and price tag of the Apogee deal, with debate over whether AbbVie will create enough value to justify the $10.9 billion acquisition. AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal

Analyst Ratings Changes

Several brokerages recently commented on ABBV. Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday. Canaccord Genuity Group boosted their price objective on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a report on Tuesday. William Blair reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Stock Performance

The stock has a fifty day simple moving average of $213.64 and a two-hundred day simple moving average of $218.83. The stock has a market cap of $430.47 billion, a price-to-earnings ratio of 120.02, a P/E/G ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.46 earnings per share. Equities analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 340.89%.

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently bought and sold shares of ABBV. Chelsea Counsel Co. acquired a new stake in shares of AbbVie during the third quarter valued at about $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the fourth quarter valued at approximately $28,000. Westend Capital Management LLC bought a new position in AbbVie in the 4th quarter valued at approximately $29,000. Imprint Wealth LLC boosted its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the 3rd quarter valued at approximately $31,000. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.